CTOs on the Move

Marathon Kids

www.marathonkids.org

 
Marathon Kids is a nonprofit organization, headquartered in Austin, TX, that is dedicated to improving the health of children by providing them with the motivation, tools and support to live happier, healthier lifestyles. Marathon Kids started out with the simple mission to introduce children to the joy of running, but it has evolved into the only evidence-based running/walking program for elementary-school kids in the United States. We`ve stood up to rigorous tests to prove that our program mitigates the negative health effects of a sedentary lifestyle and ardently pushes for access around the country. The vast majority of kids don`t ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.marathonkids.org
  • 4544 South Lamar Blvd. Bldg 300 Suite 350
    Austin, TX USA 78745
  • Phone: 512.477.1259

Executives

Name Title Contact Details
Anne-Marie Tucker
 Chief Technology Officer Profile

Similar Companies

Carolina Centers for Medical Excellence

Carolina Centers for Medical Excellence is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

5 Star Nutrition

5 Star Nutrition is a provider of health and wellness products known for its personalized, high-quality service and keen military alignment.

PlayMaker Health

PlayMaker Health`s post-acute software transforms provider claims into actionable business intelligence. Integrating within existing industry workflows, the platform, and mobile-first CRM unify market and sales performance data, delivering the actionable analytics and business intelligence post-acute providers need to accelerate growth and expand competitive market share.

Sunrise Manor Nursing Home

Sunrise Manor Nursing Home is a Bay Shore, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.